Verve Therapeutics Inc (VERV) Return on Investment ROI from the first quarter of 2025 to first quarter of 2024 and for the year 2025, average high and low, overall ranking from Mar 31 2025 to Mar 31 2024 - CSIMarket
Verve Therapeutics Inc's ROI from its first quarter of 2025 to the first quarter of 2024 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Verve Therapeutics Inc's ROI in the first quarter of 2025?
Verve Therapeutics Inc recorded a cumulative net loss of $-181 million during 12 months ending in the first quarter of 2025, resulting in a negative return on investment (ROI) of -29.57%.
Within the Healthcare sector 420 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the fourth quarter of 2024 from 2273 to 3658.
In a significant development for shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV), two prominent law firms, The Rosen Law Firm and The Gross Law Firm, have issued crucial advisories regarding a securities class action lawsuit. This lawsuit encompasses all purchasers of Verve Therapeutics securities between August 9, 2022, and April 1, 2024. Both firms emphasize the urgent need for investors to secure legal counsel ahead of the looming deadline for lead plaintiff motions set for October 28, 2024.Rosen Law Firm, a globally recognized entity specializing in investor rights, underscores the importance of this upcoming deadline as it pertains to individuals who purchased shares of Verve Therapeutics during the aforementioned class period. The firm has previously been involved in high-profile securities litigations, advocating fiercely for investors rights amidst legal complexities. Their alert serves to remind shareholders of their potential claims and the need for proactive participation in the proceedings.
Lead Plaintiff Deadline Approaches for Verve Therapeutics, Inc. Lawsuit: The Gross Law Firm Calls on Shareholders to Take Action by October 28, 2024 New York, September 10, 2024 The Gross Law Firm, a prominent securities litigation firm, has issued an urgent reminder to shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV). The firm emphasizes the critical lead plaintiff deadline of October 28, 2024, for the ongoing class-action lawsuit against Verve Therapeutics, Inc. This development signals a pivotal moment for shareholders seeking justice and redress for potential securities law violations committed by the company. Background of the Legal Action Verve Therapeutics, Inc. renowned for its innovative approach to genetic medicines designed to treat cardiovascular diseases, has faced increasing scrutiny from its shareholders over alleged misleading statements and omissions. The class-action lawsuit filed against the company addresses accusations of misrepresentation related to its business practices, financial health, and operational outlook. The Gross Law Firm, known for its rigorous approach to shareholder advocacy, is spearheading the efforts to hold Verve Therapeutics accountable. The litigation focuses on several key areas of concern:1. Alleged Misleading Public Statements : Shareholders allege that Verve Therapeutics disseminated false or misleading statements regarding the efficacy and progress of its gene-editing treatments. These statements, as purported in the lawsuit, materially hurt shareholder value and market perception of the company s potential.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
